| Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome B Sjouke, DM Kusters, I Kindt, J Besseling, JC Defesche, EJG Sijbrands, ... European heart journal 36 (9), 560-565, 2014 | 512 | 2014 |
| Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus J Besseling, JJP Kastelein, JC Defesche, BA Hutten, GK Hovingh JAMA 313 (10), 1029-1036, 2015 | 406 | 2015 |
| Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers J Besseling, I Kindt, M Hof, JJP Kastelein, BA Hutten, GK Hovingh Atherosclerosis 233 (1), 219-223, 2014 | 232 | 2014 |
| Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality J Besseling, GK Hovingh, R Huijgen, JJP Kastelein, BA Hutten Journal of the American College of Cardiology 68 (3), 252-260, 2016 | 192 | 2016 |
| Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology G De Backer, J Besseling, J Chapman, GK Hovingh, JJP Kastelein, ... Atherosclerosis 241 (1), 169-175, 2015 | 190 | 2015 |
| Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study JJP Kastelein, J Besseling, S Shah, J Bergeron, G Langslet, GK Hovingh, ... The Lancet 385 (9983), 2153-2161, 2015 | 111 | 2015 |
| Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation … J Besseling, JB Reitsma, D Gaudet, D Brisson, JJP Kastelein, GK Hovingh, ... European heart journal 38 (8), 565-573, 2016 | 57 | 2016 |
| Screening and treatment of familial hypercholesterolemia–Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014) J Besseling, B Sjouke, JJP Kastelein Atherosclerosis 241 (2), 597-606, 2015 | 49 | 2015 |
| Efficacy and safety of mipomersen sodium (Kynamro) K Hovingh, J Besseling, J Kastelein Expert opinion on drug safety 12 (4), 569-579, 2013 | 38 | 2013 |
| LDL cholesterol goals in high-risk patients: how low do we go and how do we get there? J Besseling, J van Capelleveen, JJP Kastelein, GK Hovingh Drugs 73 (4), 293-301, 2013 | 25 | 2013 |
| Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy ML Hartgers, J Besseling, ES Stroes, J Wittekoek, JHW Rutten, J de Graaf, ... Journal of clinical lipidology 12 (4), 972-980. e1, 2018 | 21 | 2018 |
| Intestinal cholesterol secretion: future clinical implications L Jakulj, J Besseling, ES Stroes, AK Groen Neth J Med 71 (9), 459-465, 2013 | 21 | 2013 |
| EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of … G De Backer, J Besseling, J Chapman, GK Hovingh, JJ Kastelein, ... Atherosclerosis 241 (1), 169-175, 2015 | 18 | 2015 |
| Homozygous autosomal dominant hypercholesterolemia in the Netherlands: prevalence, genotype-phenotype relationship and clinical outcome B Sjouke, D Kusters, I Kindt, J Besseling, J Defesche, E Sijbrands, ... Journal of the American College of Cardiology 63 (12S), A2050-A2050, 2014 | 15 | 2014 |
| Clinical Phenotype in Relation to the Distance-to-index-patient in Familial Hypercholesterolemia J Besseling, R Huijgen, SS Martin, BA Hutten, JJP Kastelein, GK Hovingh Atherosclerosis 246, 1-6, 2016 | 14 | 2016 |
| Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study J Besseling, J Reitsma, JA Van Erkelens, MHJ Schepens, MPC Siroen, ... Cancers 13 (145), 2021 | 11 | 2021 |
| Is there a link between diabetes and cholesterol metabolism? J Besseling, BA Hutten Expert review of cardiovascular therapy 14 (3), 259-261, 2016 | 9 | 2016 |
| Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises J Besseling, GK Hovingh, ES Stroes Neth J Med 71 (3), 118-122, 2013 | 9 | 2013 |
| predicting the presence of a mutation resulting in familial hypercholesterolemia-development of a prediction model in a cohort of 64,000 subjects J Besseling, JB Reitsma, GK Hovingh, BA Hutten Circulation 130 (suppl_2), A16172-A16172, 2014 | 4 | 2014 |
| Attainment of LDL-C treatment target in familial hypercholesterolemia patients: A theoretical model exploring efficacy of current and novel lipid lowering therapies ML Hartgers, J Besseling, GK Hovingh Atherosclerosis 252, e43-e44, 2016 | 3 | 2016 |
